...
首页> 外文期刊>International Journal of Pharmaceutics >The enhanced longevity and liver targetability of Paclitaxel by hybrid liposomes encapsulating Paclitaxel-conjugated gold nanoparticles
【24h】

The enhanced longevity and liver targetability of Paclitaxel by hybrid liposomes encapsulating Paclitaxel-conjugated gold nanoparticles

机译:包封紫杉醇偶联金纳米颗粒的混合脂质体提高紫杉醇的寿命和肝靶向性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Organic and inorganic drug delivery systems both demonstrate their own advantages and challenges in practical applications. Combining these two drug delivery strategies in one system is expected to solve their current issues and achieve desirable functions. In this paper, gold nanoparticles (GNPs) and liposomes have been chosen as the model systems to construct a hybrid system and investigate its performance for the tumor therapy of Paclitaxel (PTX). The thiol-terminated polyethylene glycol (PEG(400))-PTX derivative has been covalently modified on the surface of GNPs, followed by the encapsulation of PTX-conjugated GNPs (PTX-PEG(400)@GNPs) in liposomes. The hybrid liposomes solve the solubility and stability problems of gold conjugates and show high drug loading capacity. In vitro PTX release from the hybrid system maintains the similar sustained behavior demonstrated in its conjugates. Under the protection of a biocompatible liposome shell, encapsulated PTX shows enhanced circulation longevity and liver targetability compared to Taxol (R) and PTX-PEG(400)@GNPs suspension in the pharmacokinetic and biodistribution studies. These indicate that encapsulating drug-conjugated inorganic nanoparticles inside organic carriers maintains the superiority of both vehicles and improves the performance of hybrid systems. Although these attributes of hybrid liposomes lead to a better therapeutic capacity in a murine liver cancer model than that of the comparison groups, it shows no significant difference from Taxol (R) and conjugate suspension. This result could be due to the delayed and sustained drug release from the system. However, it indicates the promising potential for these hybrid liposomes will allow further construction of a compound preparation with improved performance that is based on their enhanced longevity and liver targetability of Paclitaxel. (C) 2014 Elsevier B.V. All rights reserved.
机译:有机和无机药物递送系统在实际应用中均显示出自身的优势和挑战。将这两种药物递送策略组合在一个系统中,有望解决它们当前的问题并实现所需的功能。在本文中,金纳米颗粒(GNP)和脂质体已被选作模型系统来构建混合系统,并研究其在紫杉醇(PTX)肿瘤治疗中的性能。巯基封端的聚乙二醇(PEG(400))-PTX衍生物已在GNP的表面上进行了共价修饰,然后将PTX偶联的GNP(PTX-PEG(400)@GNP)封装在脂质体中。杂化脂质体解决了金结合物的溶解性和稳定性问题,并显示出高载药量。从混合系统中体外释放PTX保持了其结合物中所证明的相似的持续行为。在药代动力学和生物分布研究中,与Taxol(R)和PTX-PEG(400)@GNPs悬浮液相比,在生物相容性脂质体壳的保护下,封装的PTX表现出增强的循环寿​​命和肝靶向性。这些表明在有机载体内包封药物共轭的无机纳米颗粒保持了两种载体的优越性并改善了混合系统的性能。尽管杂合脂质体的这些属性在鼠肝癌模型中的治疗能力优于比较组,但与Taxol和缀合物悬浮液没有显着差异。该结果可能是由于药物从系统中延迟释放和持续释放所致。然而,这表明这些杂合脂质体的潜在潜力将允许进一​​步构建具有改善性能的化合物制剂,这是基于它们提高的紫杉醇的寿命和肝靶向性。 (C)2014 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号